The American Thyroid Association/American Association of Clinical Endocrinologists Guidelines for Hyperthyroidism and Other Causes of Thyrotoxicosis: A European Perspective

ATA/AACE Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis. Bahn RS , Burch HB , Cooper DS , Garber JR , Greenlee MC , Klein I , Laurberg P , McDougall R , Montori VM , Rivkees SA , Ross DS , Sosa JA , Stan MN . 2011. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid, 21:593–646.

Rivkees SA , Mattison DR . 2009. Ending propylthiouracil-induced liver failure in children. N Engl J Med, 360:1574–1575.

Laurberg P , Bournaud C , Karmisholt J , Orgiazzi J . 2009. Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur J Endocrinol, 160:1–8.

Emiliano AB , Governale L , Parks M , Cooper DS . 2010. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab, 95:2227–2233.

Bartalena L , Baldeschi L , Dickinson AJ , Eckstein A , Kendall-Taylor P , Marcocci C , Mourits MP , Perros P , Boborides K , Boschi A , Curro N , Daumerie C , Kahaly GJ , Krassas G , Lane CM , Lazarus JH , Marino M , Nardi M , Neoh C , Orgiazzi J , Pearce S , Pinchera A , Pitz S , Salvi M , Sivelli P , Stahl M , von Arx G , Wiersinga WM . 2008. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid, 18:333–346.

Traisk F , Tallstedt L , Abraham-Nordling M , Andersson T , Berg G , Calissendorf J , Hallengren B , Hedner P , Lantz M , Nyström E , Ponjavic V , Taube A , Törring O , Wallin G , Äsman P , Lundell G , Thyroid Study group of TT . 96. 2009 Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab, 94:3700–3707.

Ponto KA , Zang S , Kahaly GJ . 2010. The tale of radioiodine and Graves' Orbitopathy. Thyroid, 20:785–793.

Lai A , Sassi L , Compri E , Marino F , Sivelli P , Piantanida E , Tanda ML , Bartalena L . 2010. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab, 95:1333–1337.

Thomusch O , Machens A , Sekulla CM , Ukkat J , Lippert H , Gastinger I , Dralle H . 2000. Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg, 24:1335–1341.

Gharib H , Papini E , Paschke R , Duick DS , Valcavi R , Hegedüs L , Vitti P . AACE/AME/ETA Task Force on Thyroid Nodules 2010 American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. J Endocrinol Invest, 33,Suppl. 5:1–50.

Biondi B , Cooper DS . 2008. The clinical significance of subclinical thyroid dysfunction. Endocr Rev, 29:76–131.

Bogazzi F , Bartalena L , Brogioni S , Burelli A , Grasso L , Dell'Unto E , Manetti L , Martino E . 1997. Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid, 7:541–545.

Bogazzi F , Martino E , Dell'Unto E , Brogioni S , Cosci C , Aghini-Lombardi F , Ceccarelli C , Pinchera A , Bartalena L , Braverman LE . 2003. Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest, 26:635–640.

Bogazzi F , Bartalena L , Martino E . 2010. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab, 95:2529–2535.

Loy M , Perra E , Melis A , Cianchetti ME , Piga M , Serra A , Pinna G , Mariotti S . 2007. Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Acta Radiol, 48:628–634.

Abalovich M , Amino N , Barbour LA , Cobin RH , De Groot LJ , Glinoer D , Mandel SJ . Stagnaro-Green A 2007 Management of thyroid dysfunction during pregnancy, postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 92,Suppl 8:1–47.

Laurberg P , Cerquiera C , Ovesen L , Rasmussen LB , Perrild H , Andersen S , Pedersen IB , Carle A . 2010. Iodine intake as a determinant of thyroid disorders in populations. Best Pract Res Clin Endocrinol Metab, 24:13–27.

Wartofsky L , Glinoer D , Solomon B , Nagataki S , Lagasse R , Nagayama Y , Izumi M . 1991. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid, 1:129–135.

Ljunggren JG , Törring O , Wallin G , Taube A , Tallstedt L , Hamberger B , Lundell G . 1998. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid, 8:653–659.

Watt T , Groenvold M , Rasmussen AK , Bonnema SJ , Hegedüs L , Bjorner JB , Feldt-Rasmussen U . 2006. Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol, 154:501–510.

Cooper DS , Doherty GM , Haugen BR , Kloos RT , Lee SL , Mandel SJ , Mazzaferri EL , McIver B , Pacini F , Schlumberger M , Sherman SI , Steward DL , Tuttle RM . 2009. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 19:1167–1214.

Vaidya B , Williams GR , Abraham P , Pearce SH . 2008. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol, 68:814–820Epub 2007 Oct 31

Laurberg P , Wallin G , Tallstedt L , Abraham-Nordling M , Lundell G , Torring O . 2008. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol, 158:69–75.

Hegedüs L , Smith TJ , Douglas RS , Nielsen CH . 2011. Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clin Endocrinol, 74:1–8.

Vitti P , Rago T , Mancusi F , Pallini S , Tonacchera M , Santini F , Chiovato L , Marcocci C , Pinchera A . 1992. Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves' disease. Acta Endocrinol, 126:128–131.

Vitti P . 2000. Grey scale thyroid ultrasonography in the evaluation of patients with Graves' disease. Eur J Endocrinol, 142:22–24.

Rago T , Chiovato L , Grasso L , Pinchera A , Vitti P . 2001. Thyroid ultrasonography as a tool for detecting thyroid autoimmune diseases and predicting thyroid dysfunction in apparently healthy subjects. J Endocrinol Invest, 24:763–769.

Bennedbaek FN , Hegedus L . 1997. The value of ultrasonography in the diagnosis and follow-up of subacute thyroiditis. Thyroid, 7:45–50.

Park SY , Kim EK , Kim MJ , Kim BM , Oh KK , Hong SW , Park CS . 2006. Ultrasonographic characteristics of subacute granulomatous thyroiditis. Korean J Radiol, 7:229–234.

Cappelli C , Pirola I , DeMartino E , Agosti B , Delbarba A , Castellano M , Agabiti-Rosei EA . 2007. The role of imaging in Graves' disease: a cost-effectiveness analysis. Eur J Radiol, 65:99–103.

Vitti P , Rago T , Mazzeo S , Brogioni S , Lampis M , De Liperi A , Bartolozzi C , Pinchera A , Martino E . 1995. Thyroid blood flow evaluation by color-flow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis. J Endocrinol Invest, 18:857–861.

Morosini PP , Simonella G , Mancini V , Argalia G , Lucarelli F , Montironi R , Diamanti L , Suraci V . 1998. Color Doppler sonography patterns related to histological findings in Graves' disease. Thyroid, 8:577–582.

Kurita S , Sakurai M , Kita Y , Ota T , Ando H , Kaneko S , Takamura T . 2005. Measurement of thyroid blood flow area is useful for diagnosing the cause of thyrotoxicosis. Thyroid, 15:1249–1252.

Hari Kumar KV , Pasupuleti V , Jayaraman M , Abhyuday V , Rayudu BR , Modi KD . 2009. Role of thyroid Doppler in differential diagnosis of thyrotoxicosis. Endocr Pract, 15:6–9.

Ota H , Amino N , Morita S , Kobayashi K , Kubota S , Fukata S , Kamiyama N , Miyauchi A . 2007. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. Clin Endocrinol, 67:41–45.

Erdogan MF , Anil C , Cesur M , Baskal N , Erdogan G . 2007. Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. Thyroid, 17:223–228.

Sipos JA . 2009. Advances in ultrasound for the diagnosis and management of thyroid cancer. Thyroid, 19:1363–1372.

Becker D , Bair HJ , Becker W , Günter E , Lohner W , Lerch S , Hahn EG . 1997. Thyroid autonomy with color-coded image-directed Doppler sonography: internal hypervascularization for the recognition of autonomous adenomas. J Clin Ultrasound, 25:63–69.

Boi F , Loy M , Piga M , Serra A , Atzeni F , Mariotti S . 2000. The usefulness of conventional and echo colour Doppler sonography in the differential diagnosis of toxic multinodular goitres. Eur J Endocrinol, 143:339–346.

Pedersen OM , Aardal NP , Larssen TB , Varhaug JE , Myking O , Vik-Mo H . 2000. The value of ultrasonography in predicting autoimmune thyroid disease. Thyroid, 10:251–259.

Raber W , Gessl A , Nowotny P , Vierhapper H . 2002. Thyroid ultrasound versus antithyroid peroxidase antibody determination: a cohort study of four hundred fifty-one subjects. Thyroid, 12:725–731.

Schiemann U , Gellner R , Riemann B , Schierbaum G , Menzel J , Domschke W , Hengst K . 1999. Standardized grey scale ultrasonography in Graves' disease: correlation to autoimmune activity. Eur J Endocrinol, 141:332–336.

Baldini M , Orsatti A , Bonfanti MT , Castagnone D , Cantalamessa L . 2005. Relationship between the sonographic appearance of the thyroid and the clinical course and autoimmune activity of Graves' disease. J Clin Ultrasound, 33:381–385.

Zingrillo M , D'Aloiso L , Ghiggi MR , Di Cerbo A , Chiodini I , Torlontano M , Liuzzi A . 1996. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence? Clin Endocrinol, 45:201–206.

Yeh HC , Futterweit W , Gilbert P . 1996. Micronodulation: ultrasonographic sign of Hashimoto thyroiditis. J Ultrasound Med, 15:813–819.

Baldini M , Castagnone D , Rivolta R , Meroni L , Pappalettera M , Cantalamessa L . 1997. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease. Thyroid, 7:823–828.

Castagnone D , Rivolta R , Rescalli S , Baldini MI , Tozzi R , Cantalamessa L . 1996. Color Doppler sonography in Graves' disease: value in assessing activity of disease and predicting outcome. AJR Am J Roentgenol, 166:203–207.

Ueda M , Inaba M , Kumeda Y , Nagasaki T , Hiura Y , Tahara H , Onoda N , Ishikawa T , Nishizawa Y . 2005. The significance of thyroid blood flow at the inferior thyroid artery as a predictor for early Graves' disease relapse. Clin Endocrinol, 63:657–662.

Uchida T , Takeno K , Goto M , Kanno R , Kubo S , Takahashi S , Azuma K , Sakai K , Fujitani Y , Hirose T , Kawamori R , Watada H . 2010. Superior thyroid artery mean peak systolic velocity for the diagnosis of thyrotoxicosis in Japanese patients. Endocr J, 57:439–443.

Varsamidis K , Varsamidou E , Mavropoulos G . 2000. Doppler ultrasonography in predicting relapse of hyperthyroidism in Graves' disease. Acta Radiol, 41:45–48.

Hari Kumar KV , Vamsikrishna P , Verma A , Muthukrishnan J , Meena U , Modi KD . 2008. Evaluation of thyrotoxicosis during pregnancy with color flow Doppler sonography. Int J Gynaecol Obstet, 102:152–155.

Schott M , Hermsen D , Broecker-Preuss M , Casati M , Mas JC , Eckstein A , Gassner D , Golla R , Graeber C , van Helden J , Inomata K , Jarausch J , Kratzsch J , Miyazaki N , Moreno MA , Murakami T , Roth HJ , Stock W , Noh JY , Scherbaum WA , Mann K . 2009. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves' disease (GD): an international multicentre trial. Clin Endocrinol, 71:566–573.

Hermsen D , Broecker-Preuss M , Casati M , Mas JC , Eckstein A , Gassner D , van Helden J , Inomata K , Jarausch J , Kratzsch J , Mann K , Miyazaki N , Navarro Moreno MA , Murakami T , Roth HJ , Noh JY , Scherbaum WA , Schott M . 2009. Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies. Clin Chim Acta, 401:84–89.

Lytton SD , Li Y , Olivo PD , Kohn LD , Kahaly GJ . 2010. Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol, 162:438–446.

Lytton SD , Kahaly GJ . 2010. Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev, 10:116–122.

Lytton SD , Ponto KA , Kanitz M , Matheis N , Kohn LD , Kahaly GJ . 2010. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. J Clin Endocrinol Metab, 95:2123–2131.

Kamijo K , Murayama H , Uzu T , Togashi K , Kahaly GJ . 2010. A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. Thyroid, 20:851–856.

Okosieme OE , Chan D , Price SA , Lazarus JH , Premawardhana LDKE . 2010. The utility of radioiodine uptake and thyroid scintigraphy in the diagnosis and management of hyperthyroidism. Clin Endocrinol, 72:122–127.

Torizuka T , Kasagi K , Hatabu H , Misaki T , Iida Y , Konishi J , Endo K . 1993. Clinical diagnostic potentials of thyroid ultrasonography and scintigraphy: an evaluation. Endocr J, 40:329–36.

Sarkar SD . 2006. Benign thyroid disease: what is the role of nuclear medicine? Semin Nucl Med, 36:185–93.

Bogazzi F , Vitti P . 2008. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nature Rev Endocrinol, 4:70–71.

Bartalena L , Tanda ML . 2009. Clinical practice. Graves' ophthalmopathy. N Engl J Med, 360:994–1001.

Bahn RS . 2010. Graves' ophthalmopathy. N Engl J Med, 362:726–738.

Bartalena L , Pinchera A , Marcocci C . 2000. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev, 21:168–199.

Kahaly GJ . 2010. Management of moderately severe Graves' orbitopathy. Wiersinga WM , Kahaly GJ . Graves' Orbitopathy. A Multidisciplinary Approach—Questions and Answers, 2nd. Karger: Basel, 120–158.

Zang S , Ponto KA , Kahaly GJ . 2011. Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab, 96:320–332

Zang S , Kahaly GJ . 2011. Steroids, the immune response in Graves' orbitopathy. Immunol Endocr Metab Agents Med Chem, 11in press

Nygaard B , Hegedüs L , Gervil M , Hjalgrim H , Hansen BM , Søe-Jensen P , Hansen JM . 1995. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease. J Intern Med, 238:491–497.

Nygaard B , Hegedüs L , Ulriksen P , Nielsen KG , Hansen JM . 1999. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med, 159:1364–1368.

Walter MA , Briel M , Christ-Crain M , Bonnema SJ , Connell J , Cooper DS , Bucher HC , Müller-Brand J , Müller B . 2007. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomized controlled trials. BMJ, 334:514.

Bonnema SJ , Bennedbaek FN , Veje A , Marving J , Hegedüs L . 2004. Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab, 89:4439–4444.

Nielsen VE , Bonnema SJ , Boel-Jørgensen H , Grupe P , Andersen PB , Bastholt L , Hegedüs L . 2006. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med, 166:1476–1482.

Bonnema SJ , Nielsen VE , Boel-Jørgensen H , Grupe P , Andersen PB , Bastholt L , Hegedüs L . 2007. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab, 92:3424–3428.

Fast S , Hegedüs L , Grupe P , Nielsen VE , Bluhme C , Bastholt L , Bonnema SJ . 2010. Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy. J Clin Endocrinol Metab, 95:3719–3725.

Graf H , Fast S , Pacini F , Pinchera A , Leung M , Vaisman M , Reiners C , Wemeau JL , Huysmans D , Harper W , Driedger A , Noemberg de Souza H , Castagna MG , Antonangeli L , Braverman L , Corbo R , Düren C , Proust-Lemoine E , Edelbroek MA , Mariott C , Rachinsky I , Grupe P , Watt T , Magner J , Hegedüs L . 2011. Modified-release human recombinant TSH (MRrhTSH) augments the effect of ¹³¹I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study. J Clin Endocrinol Metab, 96:1368–1376.

Hegedüs L . 2009. Therapy: a new nonsurgical therapy option for benign thyroid nodules. Nat Rev Endocrinol, 9:476–478.

Døssing H , Bennedbaek FN , Bonnema SJ , Grupe P , Hegedüs L . 2007. Randomized prospective study comparing a single radioiodine dose and a single laser therapy session in autonomously functioning thyroid nodules. Eur J Endocrinol, 157:95–100.